Please login to the form below

Not currently logged in
Email:
Password:

Ultibro Breezhaler

This page shows the latest Ultibro Breezhaler news and features for those working in and with pharma, biotech and healthcare.

Novartis signs 'connected inhaler' deal with Propeller Health

Novartis signs 'connected inhaler' deal with Propeller Health

Novartis and Propeller will connect the Breezhaler devices to Propeller's digital platform via a new custom sensor will passively record and transmit treatment compliance data. ... The inhaler is currently used as part of Novartis' Ultibro Breezhaler,

Latest news

  • Vectura to merge with SkyePharma in £441m deal Vectura to merge with SkyePharma in £441m deal

    Vectura recorded revenues of £26m in the six-month period ended September 2015 - up 35% - as royalties increased on products such as Novartis' Ultibro Breezhaler (indacaterol/glycopyrronium bromide).

  • Novartis sets sights on connected inhaler Novartis sets sights on connected inhaler

    The next-generation Breezhaler falls within the pharma firm's collaboration with Qualcomm, whose Qualcomm Life subsidiary provides wireless solutions for the management of chronic diseases and sharing of medical information. ... Novartis plans a 2019

  • Novartis' combo COPD inhaler cleared in EU Novartis' combo COPD inhaler cleared in EU

    Becomes first dual action bronchodilator approved in EU for COPD. Novartis' Ultibro Breezhaler has become the first dual action bronchodilator to be approved in the EU for chronic obstructive pulmonary disease ... Many COPD patients will now have a

  • Boehringer’s first cancer drug leads EMA recommendations Boehringer’s first cancer drug leads EMA recommendations

    Novartis COPD inhaler recommended in EU. Elsewhere among the CHMP's recommendations, Novartis received backing for the Ultibro Breezhaler as a once-daily maintenance treatment to relive symptoms in adults with ... The product, which is to be marketed as

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics